Sort
10,766 grants matching “checkpoint inhibitor”
Flow Cytometry Shared Resource (FCSR)
$274,597Zoran Galic · University Of California Los Angeles · P30 · FY2021 · CA
Flow Cytometry Shared Resource (FCSR)
$274,597Zoran Galic · University Of California Los Angeles · P30 · FY2022 · CA
THE IMPACT OF CELLULAR DEFENSE ON THE ROLE OF Ku80 IN GENOME MAINTENANCE AND LONG
$274,495Edward P Hasty · Buck Institute For Research On Aging · P01 · FY2007 · AG
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
$274,204Richard M Longnecker · Northwestern University At Chicago · R01 · FY2008 · CA
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
$274,204Richard M Longnecker · Northwestern University At Chicago · R01 · FY2009 · CA
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
$274,204Richard M Longnecker · Northwestern University At Chicago · R01 · FY2010 · CA
Preclinical development of CM-CX1 for the treatment of ovarian clear cell and renal cell carcinomas
$274,085Joana M Murad · Celdara Medical, Llc · R44 · FY2021 · CA
Translation and validation of non-invasive measurement of PD-L1 levels with positron emission tomography (PET) in head and neck malignancies and intracranial metastases
$274,072Mariam Aboian · Yale University · R21 · FY2022 · CA
Fu - Proj 3
$273,666Feng Fu · Dartmouth College · P20 · FY2019 · GM
Modulation of Microglia and T Cell Interactions in Malignant Glioma
$273,600Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2024 · CA
Characterizing the immune infiltrate in muscle-invasive urothelial carcinoma
$273,561Katharine A. Collier · Ohio State University · K08 · FY2023 · CA
Characterizing the immune infiltrate in muscle-invasive urothelial carcinoma
$273,561Katharine A. Collier · Ohio State University · K08 · FY2025 · CA
Characterizing the immune infiltrate in muscle-invasive urothelial carcinoma
$273,561Katharine A. Collier · Ohio State University · K08 · FY2024 · CA
Discovery of New Treatment Options for EBV-associated Lymphoma and PTLD
$273,533Richard M Longnecker · Northwestern University At Chicago · R01 · FY2012 · CA
pBACH1 binding site on BRCT(BRCA1): A novel approach to cancer therapeutics
$273,497Amarnath Natarajan · University Of Nebraska Medical Center · R01 · FY2009 · CA
Modulation of metabolism in TILs by the checkpoint inhibitor PSGL-1
$273,488Linda Mac Pherson Bradley · Sanford Burnham Prebys Medical Discovery Institute · R21 · FY2020 · CA
Suppression of translocations by RecQ-like DNA helicases
$273,339Kristina Schmidt · University Of South Florida · R01 · FY2012 · GM
Flow Cytometry Shared Resource (FCSR)
$273,136Zoran Galic · University Of California Los Angeles · P30 · FY2020 · CA
The SIK2 Inhibitor GRN-300 Enhances PARP Inhibitor Sensitivity and Cytotoxic T-Cell Function in Ovarian Cancer
$273,112Robert C Bast · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA
Targeting EGFL6 in Ovarian Cancer
$273,109Anil K Sood · University Of Tx Md Anderson Can Ctr · P50 · FY2025 · CA
Mechanisms of resistance to immune therapy in NSCLC
$273,000Qingsheng Li · University Of Louisville · P20 · FY2020 · GM
Control of Mitotic Entry by Regulators of Cdc2
$273,000Sally A Kornbluth · Duke University · R01 · FY2008 · GM
Control of Mitotic Entry by Regulators of Cdc2
$273,000Sally A Kornbluth · Duke University · R01 · FY2009 · GM
Control of Mitotic Entry by Regulators of Cdc2
$273,000Sally A Kornbluth · Duke University · R01 · FY2007 · GM
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine
$273,000Kavitha Yaddanapudi · University Of Louisville · P20 · FY2020 · GM